PISCATAWAY, N.J. — Kon Ostaliciuk is a well-respected veteran with over 25 years of experience in the generic pharmaceuticals industry. He began his career at Sidmak Laboratories in East Hanover, N.J. and subsequently served as vice president of sales and marketing at Breckenridge Pharmaceuticals, Able Laboratories and Boca Pharmaceuticals.
He joined Camber Pharmaceuticals in 2009 and currently serves as its president. Under his leadership, Camber has grown into one of the largest distributors of generic medications in the United States.
He recently spoke with CDR about Camber, its background and its future.
CDR: Please describe Camber’s background and growth story.
Ostaliciuk: Camber is currently one of the larger and fastest-growing companies in the generic pharmaceutical industry. Camber is a wholly owned subsidiary of Hetero, headquartered in Hyderabad, India, and privately held by B.P.S. Reddy and his family.
Hetero is a global leader in creating APIs (active pharmaceutical ingredients) as well as the production of branded and generic pharmaceuticals worldwide.
From KSMs (key starting materials) to APIs to finished dosage pharmaceuticals, Hetero manufactures high-quality U.S. FDA-approved generic molecules in various delivery forms, including tablets, capsules, soft gels, liquids and injectables.
Camber was launched in 2007 and has its headquarters and two distribution facilities in Piscataway, N.J. Since its launch, the company has grown rapidly and now offers a portfolio of more than 250 generic products and over 800 SKUs across multiple therapeutic categories. Camber has also surpassed the billion-dollar mark in annual sales, reflecting strong demand for its products and the trust of customers throughout the U.S. market.
To support continued growth, Camber has expanded its distribution infrastructure in New Jersey and continues to invest in additional capacity to support future product launches and portfolio expansion. Camber credits its success to the support of its parent company and the strength and experience of its associates.
CDR: What role has vertical integration played in Camber's growth?
Ostaliciuk: Camber is one of the most vertically integrated companies in the generic pharmaceutical industry. As a result of its extensive capabilities, Camber has been able to develop products at a faster pace while maintaining control over processes at every stage, without being dependent on other companies for key materials used in development and manufacturing. Vertical integration will continue to be a major factor in enabling Camber to grow and remain highly competitive in the U.S. market.
CDR: Last year was one of exceptional growth for Camber. What were some of the major highlights?
OSTAFICIUK: Camber continued to support the needs of its customers throughout 2025 while also bringing key molecules such as Eltrombopag and others to market. As a significant participant in the U.S. generics market, Camber was also able to negotiate several licensing agreements with major branded multinational pharmaceutical companies to expand its portfolio.
Continued investment in marketing efforts and the growth and development of our associates have also contributed to the company's progress in 2025, into 2026, and for the future. In addition, Camber continues to expand its portfolio to include more complex therapies, including large-molecule and oncology products, further strengthening the company's position in the U.S. generics market.
CDR: Looking ahead, what are Camber's goals and priorities?
Ostaliciuk: Camber's top priority is always its customers.
While many companies emphasize quality, service and price as the keys to success, Camber believes these are essential expectations rather than differentiators. Our goal is to go beyond those basics and continually strive to be the best generics company in the United States. This vision starts with our chairman, Partha Reddy and our managing director, Vamsi Reddy and extends to every associate at Camber.
CDR: What segments of the generics marketplace represent important opportunities for Camber?
Ostaliciuk: Conventional generic pharmaceuticals and controlled substance generics continue to be the "bread and butter" of Camber's business. Our specialty division, Camber Specialty, which already offers a growing portfolio of injectable generics, as well as our consumer care/0-T-C division, Camber Consumer Care, represent important growth opportunities for the company. In the future, Camber also plans to introduce several biosimilar products, which will be developed and manufactured by our parent company, Hetero and marketed by Camber in the coming years.
CDR: What role does your O-T-C business play in Camber's strategy? What opportunities are you targeting in that sector?
Ostaliciuk: Camber already has an established O-T-C business through Camber Consumer Care. The company will continue to expand and develop its O-T-C portfolio to meet the evolving needs and demands of its customers.
CDR: Looking ahead, how do you view the pharma industry and Camber's role in it?
Ostaliciuk: Camber Pharmaceuticals will continue to grow and make strategic investments to ensure that it remains one of the leading suppliers of generic pharmaceuticals in the United States and Puerto Rico for many years to come. Camber has a strong commitment to the generic pharmaceutical industry and will continue to dedicate the resources needed to expand its portfolio and develop, manufacture and supply high-quality generics as well as more complex molecules in the future.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
